Clostridium difficile: Deleterious impact on hematopoietic stem cell transplantation

Current Hematologic Malignancy Reports

Volumn 9, Issue 1, 2014, Pages 85-90

  Callejas Díaz, Alejandro ^a   Gea Banacloche, Juan C ^b  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

C difficile infection; C. difficile; CDI; Clostridium difficile associated disease; Diagnosis; Diarrhea; Epidemiology; Hematologic malignancies; Hematopoietic stem cell transplant; Immunosuppressed; Outcomes; Treatment

Indexed keywords

ALBUMIN; CEPHALOSPORIN DERIVATIVE; DOXYCYCLINE; FIDAXOMICIN; LEVOFLOXACIN; METRONIDAZOLE; NITAZOXANIDE; PIPERACILLIN PLUS TAZOBACTAM; PROTON PUMP INHIBITOR; RIFAXIMIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BODY TEMPERATURE; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CYTOTOXICITY ASSAY; DIARRHEA; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEVER; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; LEUKOCYTE COUNT; NEUTROPENIA; NONHUMAN; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 84896718220     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-013-0193-y     Document Type: Article

References (34)

1. Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short- and long-term attributable costs of clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46(4):497-504. (Pubitemid 351263485)
2. Centers for Disease Control and Prevention (CDC). Vital signs: preventing clostridium difficile infections. MMWR Morb Mortal Wkly Rep. 2012;61(9):157-62.
3. Lessa FC, Gould CV, McDonald LC. Current status of clostridium difficile infection epidemiology. Clin Infect Dis. 2012;55 Suppl 2:S65-70.
4. Dubberke ER, Reske KA, Srivastava A, Sadhu J, Gatti R, Young RM, et al. Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant. 2010;24(2):192-8.
5. Chakrabarti S, Lees A, Jones SG, Milligan DW. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant. 2000;26(8):871-6.
6. • Alonso CD, Treadway SB, Hanna DB, Huff CA, Neofytos D, Carroll KC, et al. Epidemiology and outcomes of clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012;54(8):1053-63. Retrospective case-control study of 999 patients with HSCTwhere the role of prior colonization with C. difficile is highlighted as a possible explanation to the early onset of CDI in this population. The reciprocal relationship between CDI and GVHD is examined.
7. • Trifilio SM, Pi J, Mehta J. Changing epidemiology of clostridium difficile-associated disease during stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(3):405-9. Restrospective observational study of 822 HSCT to describe incidence of CDI in this population and the main risk factors. The Cox regresion analysis showed that the age >60 years, allogeneic HSCTand prior colonization with VRE increased the risk of CDI. The authors developed a risk stratification model based on these criteria.
8. • Alonso CD, Dufresne SF, Hanna DB, Labbé AC, Treadway SB, Neofytos D, et al. Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors. Biol Blood Marrow Transplant. 2013;19(10):1502-8. Retrospective study of 873 autologous HSCTwhere mucositis grade >2 was the strongest risk factor to develop CDI in the multivariate analysis.
9. •• Willems L, Porcher R, Lafaurie M, Casin I, Robin M, Xhaard A, et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 2012;18(8):1295-301. This is the one recent paper on CDI after allogeneic HSCT. Use of cord blood, presence of GVHD and total body irradiation were independent risk factors in the multivariate analysis. There were strict definitions of CDI. Oral metronidazole was almost always successfully used.
10. •• Kamboj M, Son C, Cantu S, Chemaly RF, Dickman J, Dubberke E, et al. Hospital-onset clostridium difficile infection rates in persons with cancer or hematopoietic stem cell transplant: a C3IC network report. Infect Control Hosp Epidemiol. 2012;33(11):1162-5. This survey of 11 cancer centers found the incidence of hospital-acquired CDI was twice as high in cancer patients than in the general hospital population and demonstrate that the test used to detect C. difficile can affect this rate.
11. • Parmar SR, Bhatt V, Yang J, Zhang Q, Schuster M. A retrospective review of metronidazole and vancomycin in the management of clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract 2013. Retrospective study of 390 patients with hematologic malignancies, including 27 patients with HSCT to determinate the incidence of CDI and differences in outcome pending on the treatment used. The study showed no differences between metronidazole and vancomycin but a better outcome in patients in which previous antibiotics were stopped.
12. Leung S, Metzger BS, Currie BP. Incidence of clostridium difficile infection in patients with acute leukemia and lymphoma after allogeneic hematopoietic stem cell transplantation. Infect Control Hosp Epidemiol. 2010;31(3):313-5.
13. •• Chopra T, Chandrasekar P, Salimnia H, Heilbrun LK, Smith D, Alangaden GJ. Recent epidemiology of clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant. 2011;25(1):E82-7. This is a retrospective study to describe the epidemiology of CDE in 361 patients with HSCT that is one of the first and larger studies on the topic. It found that CDI rates are nine-fold higher in HSCT patients that those in general patients.
14. Alonso CD, Marr KA. Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis. Curr Opin Infect Dis. 2013;26(4):326-31.
15. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-55.
16. •• Debast SB, Bauer MP, Kuijper EJ. The committee. European society of clinical microbiology and infectious diseases (ESCMID): update of the treatment guidance document for clostridium difficile infection (CDI). Clin Microbiol Infect. 2013. doi:10.1111/1469-0691.12418. This is a comprehensive source of information on CDI: diagnostic tests, severity, treatment are all covered in great detail.
17. Babady NE, Stiles J, Ruggiero P, Khosa P, Huang D, Shuptar S, et al. Evaluation of the Cepheid xpert clostridium difficile epi assay for diagnosis of clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. J Clin Microbiol. 2010;48(12):4519-24.
18. Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, et al. Differences in outcome according to clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis. 2013;13(11):936-45.
19. Eriguchi Y, Takashima S, Oka H, Shimoji S, Nakamura K, Uryu H, et al. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting paneth cell production of α-defensins. Blood. 2012;120(1):223-31.
20. Paul M, Yahav D, Bivas A, Fraser A, Leibovici L. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev. 2010;11, CD005197.
21. Guthrie KA, Yong M, Frieze D, Corey L, Fredricks DN. The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45(4):675-81.
22. Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1, CD004386.
23. Bauer MP, Kuijper EJ, van Dissel JT. European society of clinical microbiology and infectious diseases. European society of clinical microbiology and infectious diseases (ESCMID): treatment guidance document for clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15(12):1067-79.
24. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302-7. (Pubitemid 47101025)
25. Dubberke ER, Sadhu J, Gatti R, Reske KA, DiPersio JF, Devine SM, et al. Severity of clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system. Infect Control Hosp Epidemiol. 2007;28(2):208-11. (Pubitemid 46374164)
26. Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, et al. Efficacy of fidaxomicin versus vancomycin as therapy for clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011;53(5):440-7.
27. •• Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for clostridium difficile infection. N Engl J Med. 2011;364(5):422-31. The main randomized controlled trial comparing fidaxomicin with vancomycin that showed fidaxomicin to be noninferior in terms of response rate, and possibly superior in terms of recurrences.
28. •• van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J Med. 2013;368(5):407-15. The most convincing paper on the efficacy of stool transplant.
29. Clutter DS, Dubrovskaya Y, Merl MY, Teperman L, Press R, Safdar A. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stemcell transplantation with clostridium difficile-associated diarrhea. Antimicrob Agents Chemother. 2013;57(9):4501-5.
30. Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S. Resolution of clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013;31(19):2493-9.
31. • Neemann K, Eichele DD, Smith PW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminant clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis. 2012;14(6):E161-5. This case report is the first publication of fecal microbiota transplantation as a part of the management of CDI that was refractory to conventional treatment in a HSCT patient.
32. Ritter AS, Petri WA. New developments in chemotherapeutic options for clostridium difficile colitis. Curr Opin Infect Dis. 2013;26(5):461-70.
33. Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee. Society for healthcare epidemiology of America. Association for professionals in infection control. Infectious diseases society of America. Hand hygiene task force. Guideline for hand hygiene in health-care settings: recommendations of the healthcare infection control practices advisory committee and the HICPAC/SHEA/APIC/IDSA hand hygiene task force. Infect Control Hosp Epidemiol. 2002;23(12 Suppl):S3-S40.
34. Vonberg RP, Kuijper EJ, Wilcox MH, Barbut F, Tüll P, Gastmeier P, et al. Infection control measures to limit the spread of clostridium difficile. Clin Microbiol Infect. 2008;14 Suppl 5:2-20. 29.